Prostate Conditions Education Council (PCEC) Comments On New AUA Clinical Guideline On Prostate Cancer Screening
DENVER, May 3, 2013 /PRNewswire-USNewswire/ -- The Prostate Conditions Education Council (PCEC), a national organization committed to men's health and a leader in prostate cancer early detection, released the following statement in response to new clinical practice guideline released today by the American Urological Association (AUA). The statement is attributed to PCEC Chairman E. David Crawford, MD, PCEC President Wendy Poage and PCEC Council Member Nelson Stone.
"PCEC applauds the American Urological Association for its diligent work on their new prostate cancer clinical practice guidelines announced today and its recognition that, as medicine continues to evolve, so must the protocols for the disease. We look forward to continuing the discussion around the best practices for the diagnosis and treatment of prostate cancer.
Guidelines, such as the AUA's, are an excellent starting place for men and their physicians. It is important to realize, however, that the landscape of prostate cancer early detection is changing rapidly, with a variety of new biomarkers currently available to better enhance the diagnosis and prognosis of prostate cancer. Therefore, screening for prostate cancer is not a one-size-fits-all proposition. PCEC's goal remains to educate men and their healthcare practitioners about prostate cancer testing and new developments, such as biomarkers, so that together they can develop a personalized plan for appropriate follow up after a baseline test. PCEC is also dedicated to ensuring that men are educated about their options for testing particularly given that many are either without health insurance or under insured, which is why PCEC holds its annual Prostate Cancer Awareness Week.
Our hope is that men will understand that knowledge is power, and that by knowing more about their prostate health, they will be able to make better and more informed choices about screening and, if necessary, the diagnosis and treatment of prostate conditions."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts